Recombinant Human BCL2L2 Protein，His

BCL2L2, also known as BCL-W, is a member of the BCL-2 family of proteins, which play a crucial role in the regulation of apoptosis, or programmed cell death. This protein is primarily expressed in various tissues, including the testis and brain, and is known for its anti-apoptotic properties, helping to promote cell survival by inhibiting apoptotic pathways. The study of BCL2L2 has gained significant interest due to its potential implications in cancer biology, where its overexpression can contribute to tumorigenesis by preventing the normal cell death that occurs in response to cellular stress and damage. Moreover, BCL2L2 has been implicated in various hematological malignancies, solid tumors, and neurodegenerative diseases, making it a critical target for therapeutic interventions. Recombinant expression of BCL2L2 allows for detailed functional analysis and structure-function studies, thereby aiding in the development of BCL2L2 inhibitors as potential cancer treatments. Furthermore, the investigation of its interactions with other proteins within the apoptotic signaling pathways continues to provide insight into the complex mechanisms of cell survival and death, which are essential for maintaining cellular homeostasis and responding to stressors. Understanding the molecular characteristics and biological significance of BCL2L2 will not only enhance our knowledge of cancer progression and resistance mechanisms but also pave the way for innovative therapeutic strategies aimed at modulating apoptosis in disease contexts. Thus, the research surrounding BCL2L2 recombinant proteins holds promise for advancing both basic science and clinical applications in oncology and beyond.